Aldose Reductase Gene Expression Is Increased in Diabetic Nephropathy

Publisher Website
Google Scholar
Abstract
Aldose reductase gene expression is increased in insulin-depen- dent diabetes mellitus (IDDM) with nephropathy. Epidemiology stud- ies in patients with IDDM and noninsulin-dependent diabetes mel- litus (NIDDM) are consistent with the hypothesis that a genetic factor(s) influences the risk for kidney disease of diabetes mellitus (KDDM). Aldose reductase (AR), the rate-limiting enzyme in the polyol pathway, is a potential candidate gene product. The present study explored the hypothesis that AR gene expression is increased in peripheral blood mononuclear cells obtained from patients with KDDM. We studied four groups of volunteers: group I, normal sub- jects; group II, IDDM without nephropathy; group III, IDDM with kidney disease; and group IV, nondiabetics with kidney disease. AR messenger ribonucleic acid was measured by a ribonuclease protec- tion assay. The results are expressed as the mean and 95% confidence interval (CI) of the AR/b-actin messenger ribonucleic acid molar ratios (AR/b-actin R). Among diabetics, the AR/b-actin R was higher in group III (0.088; CI, 0.068 - 0.108) than in group I (0.045; CI, 0.033- 0.057; P , 0.01). There were no significant differences in age, hemo- globin A1c, or duration of diabetes between groups II and III (P 5 NS). The AR/b-actin R in group III was also higher than that in group II (0.045; CI, 0.030 - 0.060; P , 0.01) or group IV (0.019; CI, 0.011- 0.027; P , 0.001). In contrast, among nondiabetics, AR/b-actin R values were 2-fold lower in group IV than in group I (P , 0.01). The results of this study are consistent with the hypothesis that the degree of AR gene expression modulates the risk of KDDM. (J Clin Endocrinol Metab 82: 2294 -2298, 1997)

This publication has 0 references indexed in Scilit: